"It was a great experience for me working with Bentham Science Publishers because of the following reasons:
-High quality services
-Great and kind cooperation and collaboration"
Dr. Helmy Selman (The CIVF Center Doha Center Clinic Hospital Doha, Qatar)
"I would like to express to you and the whole staff of the Current Pharmaceutical Biotechnology journal my gratitude for the excellent help and support during submission, review and publication process. Thank you so much."
Professor. Edward Ratovitski (Head and Neck Cancer Research, Johns Hopkins University School of Medicine, Baltimore, USA)
"Recently, I had a nice experience through the publication of a paper in the Current Pharmaceutical Biotechnology. I would like to take this opportunity to acknowledge the Editor in-chief of the Current pharmaceutical Biotechnology, and especially Publication Manager Ms. Sumaiya Azhar for her outstanding professionalism, kindness and availability in the management of the peer review process and the editing the manuscript. I really appreciate this nice moment."
Dr. Jin Bo Su (INSERM U955 EQUIPE 3 ENVA, BATIMENT FERRANDO, Paris, France)
"It was great working with the Bentham Science Publishers. Moreover, the homepage is well managed; online submission has made it easier to submit an abstract, which as a result will definitely attract more researchers.
Dr. Ajay Vikram Singh (Department of Biomedical Engineering, Troy, New York, USA)
Davide Prosperi Department of Biotechnology and Bioscience University of Milano-Bicocca Milano Italy
Prof. Davide Prosperi is Associate Professor in Biochemistry at the University of Milano Bicocca (Unimib), Department of Biotechnology and Bioscience. Head of the NanoBioLab of Unimib, he is devoted to biomedical and biophysical applications of nanotechnology. In particular, the research activity of Davide Prosperi involves the design, synthesis, functionalization and characterization of colloidal, polymeric and biomimetic nanoparticles for biomedical applications, with particular focus on the diagnosis and treatment of cancer and inflammatory diseases. He is author of over 100 scientific publications. He is one of the author of the patent “Nanoconstructs with pharmacological activity” (n° WO2014013473-A1), and co-founder of the spin-off company inTHEna srl, aiming to design and development of molecules, nanostructures and technologies for biomedical studies and diagnosis, prevention and therapy of human and animal diseases.